Congenital vitamin K-dependent coagulation factors deficiency Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

📰

1Recent news

Regulatory Watchboard

1 event

May 2018

ANDEXXA: FDA approved

Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Congenital vitamin K-dependent coagulation factors deficiency.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

TOBRADEX ST

(TOBRAMYCIN / DEXAMETHASONE)standard

Harrow Eye, LLC

Corticosteroid [EPC]

12.1 Mechanism of Action Dexamethasone is a potent corticoid. Corticoids suppress the inflammatory response to a variety of agents and they can delay ...

FDA label ↗

View full treatment details on disease page →